Genetic variation of clock genes and cancer risk: A field synopsis and meta-analysis

Oncotarget

Volumn 8, Issue 14, 2017, Pages 23978-23995

  Benna, Clara ^a   Helfrich Förster, Charlotte ^b   Rajendran, Senthilkumar ^a   Monticelli, Halenya ^c   Pilati, Pierluigi ^d   Nitti, Donato ^a,c   Mocellin, Simone ^a,e  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^d S ANTONIO HOSPITAL   (Italy)

^e VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

Author keywords

Cancer risk; Circadian rhythms; Clock genes; Meta analysis; SNP

Indexed keywords

RETINOID RELATED ORPHAN RECEPTOR ALPHA; RETINOID RELATED ORPHAN RECEPTOR BETA; TRANSCRIPTION FACTOR CLOCK;

BREAST CANCER; CANCER RISK; CANCER SUSCEPTIBILITY; CHRONIC LYMPHATIC LEUKEMIA; CLOCK GENE; COLORECTAL CANCER; CRY GENE; ETHNICITY; GENE; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIATION; GLIOMA; HIGH RISK POPULATION; HUMAN; NON SMALL CELL LUNG CANCER; NONHODGKIN LYMPHOMA; NPAS2 GENE; OVARY CANCER; PANCREAS CANCER; PER3 GENE; PROSTATE CANCER; REVIEW; RISK ASSESSMENT; RORA GENE; RORB GENE; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMATIC REVIEW; ADULT; CIRCADIAN RHYTHM; FEMALE; GENETICS; META ANALYSIS; NEOPLASM; PATHOLOGY; RISK FACTOR;

ADULT; CIRCADIAN CLOCKS; FEMALE; GENETIC VARIATION; HUMANS; NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS;

EID: 85017037074     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.15074     Document Type: Review

References (117)

1. Foster RG, Kreitzman L. The rhythms of life: what your body clock means to you!. Experimental physiology. 2014; 99: 599-606.
2. Merbitz-Zahradnik T, Wolf E. How is the inner circadian clock controlled by interactive clock proteins?: Structural analysis of clock proteins elucidates their physiological role. FEBS letters. 2015; 589: 1516-1529.
3. Storch KF, Lipan O, Leykin I, Viswanathan N, Davis FC, Wong WH, Weitz CJ. Extensive and divergent circadian gene expression in liver and heart. Nature. 2002; 417: 78-83.
4. Koike N, Yoo SH, Huang HC, Kumar V, Lee C, Kim TK, Takahashi JS. Transcriptional architecture and chromatin landscape of the core circadian clock in mammals. Science (New York, N.Y.). 2012; 338: 349-354.
5. Ercolani L, Ferrari A, De Mei C, Parodi C, Wade M, Grimaldi B. Circadian clock: Time for novel anticancer strategies?. Pharmacological research. 2015; 100: 288-295.
6. Karatsoreos IN. Links between Circadian Rhythms and Psychiatric Disease. Frontiers in behavioral neuroscience. 2014; 8: 162.
7. Laermans J, Depoortere I. Chronobesity: role of the circadian system in the obesity epidemic. Obesity reviews. 2016; 17: 108-125.
8. Schnell A, Albrecht U, Sandrelli F. Rhythm and mood: relationships between the circadian clock and mood-related behavior. Behavioral neuroscience. 2014; 128: 326-343.
9. Kiss Z, Ghosh PM. Circadian rhythmicity and the influence of 'clock' genes on prostate cancer. Endocrine-related cancer. 2016.
10. Siracusa LD, Bussard KM. The Clock Is Ticking: Countdown to Metastases. PLoS genetics. 2016; 12: e1006299.
11. Altman BJ. Cancer Clocks Out for Lunch: Disruption of Circadian Rhythm and Metabolic Oscillation in Cancer. Frontiers in cell and developmental biology. 2016; 4: 62.
12. Blakeman V, Williams JL, Meng QJ, Streuli CH. Circadian clocks and breast cancer. Breast Cancer Res. 2016; 18: 89-016-0743-z.
13. Mukherji A, Kobiita A, Damara M, Misra N, Meziane H, Champy MF, Chambon P. Shifting eating to the circadian rest phase misaligns the peripheral clocks with the master SCN clock and leads to a metabolic syndrome. Proceedings of the National Academy of Sciences of the United States of America. 2015; 112: E6691-8.
14. Mukherji A, Kobiita A, Chambon P. Shifting the feeding of mice to the rest phase creates metabolic alterations, which, on their own, shift the peripheral circadian clocks by 12 hours. Proceedings of the National Academy of Sciences of the United States of America. 2015; 112: E6683-90.
15. Papagiannakopoulos T, Bauer MR, Davidson SM, Heimann M, Subbaraj L, Bhutkar A, Bartlebaugh J, Vander Heiden MG, Jacks T. Circadian Rhythm Disruption Promotes Lung Tumorigenesis. Cell metabolism. 2016; 24: 324-331.
16. Straif K, Baan R, Grosse Y, Secretan B, El Ghissassi F, Bouvard V, Altieri A, Benbrahim-Tallaa L, Cogliano V. Carcinogenicity of shift-work, painting, and fire-fighting. The Lancet.Oncology. 2007; 8: 1065-1066.
17. King DP, Zhao Y, Sangoram AM, Wilsbacher LD, Tanaka M, Antoch MP, Steeves TD, Vitaterna MH, Kornhauser JM, Lowrey PL, Turek FW, Takahashi JS. Positional cloning of the mouse circadian clock gene. Cell. 1997; 89: 641-653.
18. Suzuki T, Ishikawa A, Yoshimura T, Namikawa T, Abe H, Honma S, Honma K, Ebihara S. Quantitative trait locus analysis of abnormal circadian period in CS mice. Mammalian genome. 2001; 12: 272-277.
19. Hsu DS, Zhao X, Zhao S, Kazantsev A, Wang RP, Todo T, Wei YF, Sancar A. Putative human blue-light photoreceptors hCRY1 and hCRY2 are flavoproteins. Biochemistry. 1996; 35: 13871-13877.
20. Shearman LP, Zylka MJ, Weaver DR, Kolakowski LF,Jr, Reppert SM. Two period homologs: circadian expression and photic regulation in the suprachiasmatic nuclei. Neuron. 1997; 19: 1261-1269.
21. Tei H, Okamura H, Shigeyoshi Y, Fukuhara C, Ozawa R, Hirose M, Sakaki Y. Circadian oscillation of a mammalian homologue of the Drosophila period gene. Nature. 1997; 389: 512-516.
22. Reick M, Garcia JA, Dudley C, McKnight SL. NPAS2: an analog of clock operative in the mammalian forebrain. Science (New York, N.Y.). 2001; 293: 506-509.
23. Yu W, Ikeda M, Abe H, Honma S, Ebisawa T, Yamauchi T, Honma K, Nomura M. Characterization of three splice variants and genomic organization of the mouse BMAL1 gene. Biochemical and biophysical research communications. 1999; 260: 760-767.
24. Ikeda M, Nomura M. cDNA Cloning and Tissue-Specific Expression of a Novel Basic Helix-Loop-Helix/PAS Protein (BMAL1) and Identification of Alternatively Spliced Variants with Alternative Translation Initiation Site Usage. Biochemical and biophysical research communications. 1997; 233: 258-264.
25. Bunger MK, Wilsbacher LD, Moran SM, Clendenin C, Radcliffe LA, Hogenesch JB, Simon MC, Takahashi JS, Bradfield CA. Mop3 Is an Essential Component of the Master Circadian Pacemaker in Mammals. Cell. 2000; 103: 1009-1017.
26. Sato TK, Panda S, Miraglia LJ, Reyes TM, Rudic RD, McNamara P, Naik KA, FitzGerald GA, Kay SA, Hogenesch JB. A functional genomics strategy reveals Rora as a component of the mammalian circadian clock. Neuron. 2004; 43: 527-537.
27. Preitner N, Damiola F, Lopez-Molina L, Zakany J, Duboule D, Albrecht U, Schibler U. The orphan nuclear receptor REV-ERBalpha controls circadian transcription within the positive limb of the mammalian circadian oscillator. Cell. 2002; 110: 251-260.
28. Bugge A, Feng D, Everett LJ, Briggs ER, Mullican SE, Wang F, Jager J, Lazar MA. Rev-erbalpha and Reverbbeta coordinately protect the circadian clock and normal metabolic function. Genes & development. 2012; 26: 657-667.
29. Cho H, Zhao X, Hatori M, Yu RT, Barish GD, Lam MT, Chong LW, DiTacchio L, Atkins AR, Glass CK, Liddle C, Auwerx J, Downes M, et al. Regulation of circadian behaviour and metabolism by REV-ERB-alpha and REVERB-beta. Nature. 2012; 485: 123-127.
30. Liu AC, Tran HG, Zhang EE, Priest AA, Welsh DK, Kay SA. Redundant function of REV-ERBalpha and beta and non-essential role for Bmal1 cycling in transcriptional regulation of intracellular circadian rhythms. PLoS genetics. 2008; 4: e1000023.
31. Sangoram AM, Saez L, Antoch MP, Gekakis N, Staknis D, Whiteley A, Fruechte EM, Vitaterna MH, Shimomura K, King DP, Young MW, Weitz CJ, Takahashi JS. Mammalian circadian autoregulatory loop: a timeless ortholog and mPer1 interact and negatively regulate CLOCK-BMAL1-induced transcription. Neuron. 1998; 21: 1101-1113.
32. Fu L, Lee CC. The circadian clock: pacemaker and tumour suppressor. Nature reviews.Cancer. 2003; 3: 350-361.
33. Sahar S, Sassone-Corsi P. Metabolism and cancer: the circadian clock connection. Nature reviews.Cancer. 2009; 9: 886-896.
34. Stevens RG, Zhu Y. Electric light, particularly at night, disrupts human circadian rhythmicity: is that a problem?. Philosophical transactions of the Royal Society of London. Series B, Biological sciences. 2015; 370: 10.1098/ rstb.2014.0120.
35. Zhu Y, Brown HN, Zhang Y, Stevens RG, Zheng T. Period3 structural variation: a circadian biomarker associated with breast cancer in young women. Cancer Epidemiol Biomarkers Prev. 2005; 14: 268-270.
36. Zhu Y, Leaderer D, Guss C, Brown HN, Zhang Y, Boyle P, Stevens RG, Hoffman A, Qin Q, Han X, Zheng T. Ala394Thr polymorphism in the clock gene NPAS2: a circadian modifier for the risk of non-Hodgkin's lymphoma. International journal of cancer.Journal international du cancer. 2007; 120: 432-435.
37. Chu L, Zhu Y, Yu K, Zheng T, Yu H, Zhang Y, Sesterhenn I, Chokkalingam A, Danforth K, Shen M. Variants in circadian genes and prostate cancer risk: a population-based study in China. Prostate cancer and prostatic diseases. 2008; 11: 342-348.
38. Hoffman AE, Yi CH, Zheng T, Stevens RG, Leaderer D, Zhang Y, Holford TR, Hansen J, Paulson J, Zhu Y. CLOCK in breast tumorigenesis: genetic, epigenetic, and transcriptional profiling analyses. Cancer research. 2010; 70: 1459-1468.
39. Kettner NM, Katchy CA, Fu L. Circadian gene variants in cancer. Annals of Medicine. 2014; 46: 208-220.
40. Ioannidis JP, Boffetta P, Little J, O'Brien TR, Uitterlinden AG, Vineis P, Balding DJ, Chokkalingam A, Dolan SM, Flanders WD, Higgins JP, McCarthy MI, McDermott DH, et al. Assessment of cumulative evidence on genetic associations: interim guidelines. International journal of epidemiology. 2008; 37: 120-132.
41. Little J, Higgins J, Bray M, Ioannidis J, Khoury M, Manolio T, Smeeth L, Sterne J. The HuGENet™ HuGE review handbook, version 1.0. Ottawa, Ontario, Canada: HuGENet Canada Coordinating Centre. 2006.
42. Sagoo GS, Little J, Higgins JP. Systematic reviews of genetic association studies. Human Genome Epidemiology Network. PLoS medicine. 2009; 6: e28.
43. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. European journal of epidemiology. 2010; 25: 603-605.
44. Thakkinstian A, McElduff P, D'Este C, Duffy D, Attia J. A method for meta-analysis of molecular association studies. Statistics in medicine. 2005; 24: 1291-1306.
45. Zhang B, Beeghly-Fadiel A, Long J, Zheng W. Genetic variants associated with breast-cancer risk: comprehensive research synopsis, meta-analysis, and epidemiological evidence. The Lancet.Oncology. 2011; 12: 477-488.
46. Chatzinasiou F, Lill CM, Kypreou K, Stefanaki I, Nicolaou V, Spyrou G, Evangelou E, Roehr JT, Kodela E, Katsambas A, Tsao H, Ioannidis JP, Bertram L, et al. Comprehensive field synopsis and systematic meta-analyses of genetic association studies in cutaneous melanoma. Journal of the National Cancer Institute. 2011; 103: 1227-1235.
47. Theodoratou E, Montazeri Z, Hawken S, Allum GC, Gong J, Tait V, Kirac I, Tazari M, Farrington SM, Demarsh A, Zgaga L, Landry D, Benson HE, et al. Systematic metaanalyses and field synopsis of genetic association studies in colorectal cancer. Journal of the National Cancer Institute. 2012; 104: 1433-1457.
48. Wacholder S, Chanock S, Garcia-Closas M, El Ghormli L, Rothman N. Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. Journal of the National Cancer Institute. 2004; 96: 434-442.
49. Cotterchio M, Lowcock E, Bider-Canfield Z, Lemire M, Greenwood C, Gallinger S, Hudson T. Association between Variants in Atopy-Related Immunologic Candidate Genes and Pancreatic Cancer Risk. PloS one. 2015; 10: e0125273.
50. Couto P, Miranda D, Vieira R, Vilhena A, De Marco L, Bastos-Rodrigues L. Association between CLOCK, PER3 and CCRN4L with non-small cell lung cancer in Brazilian patients. Molecular medicine reports. 2014; 10: 435-440.
51. Dai H, Zhang L, Cao M, Song F, Zheng H, Zhu X, Wei Q, Zhang W, Chen K. The role of polymorphisms in circadian pathway genes in breast tumorigenesis. Breast cancer research and treatment. 2011; 127: 531-540.
52. Fu A, Leaderer D, Zheng T, Hoffman AE, Stevens RG, Zhu Y. Genetic and epigenetic associations of circadian gene TIMELESS and breast cancer risk. Molecular carcinogenesis. 2012; 51: 923-929.
53. Grundy A, Schuetz JM, Lai AS, Janoo-Gilani R, Leach S, Burstyn I, Richardson H, Brooks-Wilson A, Spinelli JJ, Aronson KJ. Shift work, circadian gene variants and risk of breast cancer. Cancer epidemiology. 2013; 37: 606-612.
54. Hoffman AE, Zheng T, Stevens RG, Ba Y, Zhang Y, Leaderer D, Yi C, Holford TR, Zhu Y. Clock-cancer connection in non-Hodgkin's lymphoma: a genetic association study and pathway analysis of the circadian gene cryptochrome 2. Cancer research. 2009; 69: 3605-3613.
55. Hoffman AE, Zheng T, Yi CH, Stevens RG, Ba Y, Zhang Y, Leaderer D, Holford T, Hansen J, Zhu Y. The core circadian gene Cryptochrome 2 influences breast cancer risk, possibly by mediating hormone signaling. Cancer prevention research (Philadelphia, Pa.). 2010; 3: 539-548.
56. Hunter DJ, Kraft P, Jacobs KB, Cox DG, Yeager M, Hankinson SE, Wacholder S, Wang Z, Welch R, Hutchinson A. A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nature genetics. 2007; 39: 870-874.
57. Jim HS, Lin HY, Tyrer JP, Lawrenson K, Dennis J, Chornokur G, Chen Z, Chen AY, Permuth-Wey J, Aben KK, Anton-Culver H, Antonenkova N, Bruinsma F, et al. Common Genetic Variation in Circadian Rhythm Genes and Risk of Epithelial Ovarian Cancer (EOC). Journal of genetics and genome research. 2015; 2: 017. Epub 2015 Sep 15.
58. Karantanos T, Theodoropoulos G, Gazouli M, Vaiopoulou A, Karantanou C, Stravopodis DJ, Bramis K, Lymperi M, Pektasidis D. Association of the clock genes polymorphisms with colorectal cancer susceptibility. Journal of surgical oncology. 2013; 108: 563-567.
59. Li J, Humphreys K, Heikkinen T, Aittomaki K, Blomqvist C, Pharoah PD, Dunning AM, Ahmed S, Hooning MJ, Martens JW, van den Ouweland AM, Alfredsson L, Palotie A, et al. A combined analysis of genome-wide association studies in breast cancer. Breast cancer research and treatment. 2011; 126: 717-727.
60. Madden MH, Anic GM, Thompson RC, Nabors LB, Olson JJ, Browning JE, Monteiro AN, Egan KM. Circadian pathway genes in relation to glioma risk and outcome. Cancer Causes & Control. 2014; 25: 25-32.
61. Markt SC, Valdimarsdottir UA, Shui IM, Sigurdardottir LG, Rider JR, Tamimi RM, Batista JL, Haneuse S, Flynn-Evans E, Lockley SW, Czeisler CA, Stampfer MJ, Launer L, et al. Circadian clock genes and risk of fatal prostate cancer. Cancer Causes Control. 2015; 26: 25-33.
62. Monsees GM, Kraft P, Hankinson SE, Hunter DJ, Schernhammer ES. Circadian genes and breast cancer susceptibility in rotating shift workers. International journal of cancer.Journal international du cancer. 2012; 131: 2547-2552.
63. Petersen GM, Amundadottir L, Fuchs CS, Kraft P, Stolzenberg-Solomon RZ, Jacobs KB, Arslan AA, Buenode-Mesquita HB, Gallinger S, Gross M, Helzlsouer K, Holly EA, Jacobs EJ, et al. A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33. Nature genetics. 2010; 42: 224-228.
64. Rabstein S, Harth V, Justenhoven C, Pesch B, Plottner S, Heinze E, Lotz A, Baisch C, Schiffermann M, Brauch H, Hamann U, Ko Y, Bruning T, et al. Polymorphisms in circadian genes, night work and breast cancer: results from the GENICA study. Chronobiology international. 2014; 31: 1115-1122.
65. Rana S, Shahid A, Ullah H, Mahmood S. Lack of association of the NPAS2 gene Ala394Thr polymorphism (rs2305160:G>A) with risk of chronic lymphocytic leukemia. Asian Pac J Cancer Prev. 2014; 15: 7169-7174.
66. Truong T, Liquet B, Menegaux F, Plancoulaine S, Laurent-Puig P, Mulot C, Cordina-Duverger E, Sanchez M, Arveux P, Kerbrat P, Richardson S, Guenel P. Breast cancer risk, nightwork, and circadian clock gene polymorphisms. Endocrine-related cancer. 2014; 21: 629-638.
67. Wang F, Hu Z, Yang R, Tang J, Liu Y, Hemminki K, Sutter C, Wappenschmidt B, Niederacher D, Arnold N, Meindl A, Bartram CR, Schmutzler RK, et al. A variant affecting miRNAs binding in the circadian gene Neuronal PAS domain protein 2 (NPAS2) is not associated with breast cancer risk. Breast cancer research and treatment. 2011; 127: 769-775.
68. Wirth MD, Burch JB, Hebert JR, Kowtal P, Mehrotra-Kapoor A, Steck SE, Hurley TG, Gupta PC, Pednekar MS, Youngstedt SD, Zhang H, Sarin R. Case-control study of breast cancer in India: Role of PERIOD3 clock gene length polymorphism and chronotype. Cancer investigation. 2014; 32: 321-329.
69. Zhu Y, Stevens RG, Leaderer D, Hoffman A, Holford T, Zhang Y, Brown HN, Zheng T. Non-synonymous polymorphisms in the circadian gene NPAS2 and breast cancer risk. Breast cancer research and treatment. 2008; 107: 421-425.
70. Zhu Y, Stevens RG, Hoffman AE, Fitzgerald LM, Kwon EM, Ostrander EA, Davis S, Zheng T, Stanford JL. Testing the circadian gene hypothesis in prostate cancer: a population-based case-control study. Cancer research. 2009; 69: 9315-9322.
71. Zienolddiny S, Haugen A, Lie JA, Kjuus H, Anmarkrud KH, Kjaerheim K. Analysis of polymorphisms in the circadian-related genes and breast cancer risk in Norwegian nurses working night shifts. Breast Cancer Res. 2013; 15: R53.
72. Bersten DC, Sullivan AE, Peet DJ, Whitelaw ML. bHLHPAS proteins in cancer. Nature reviews.Cancer. 2013; 13: 827-841.
73. Hoffman AE, Zheng T, Ba Y, Zhu Y. The circadian gene NPAS2, a putative tumor suppressor, is involved in DNA damage response. Mol Cancer Res. 2008; 6: 1461-1468.
74. Alhopuro P, Bjorklund M, Sammalkorpi H, Turunen M, Tuupanen S, Bistrom M, Niittymaki I, Lehtonen HJ, Kivioja T, Launonen V, Saharinen J, Nousiainen K, Hautaniemi S, et al. Mutations in the circadian gene CLOCK in colorectal cancer. Mol Cancer Res. 2010; 8: 952-960.
75. Nakahata Y, Kaluzova M, Grimaldi B, Sahar S, Hirayama J, Chen D, Guarente LP, Sassone-Corsi P. The NAD+-dependent deacetylase SIRT1 modulates CLOCK-mediated chromatin remodeling and circadian control. Cell. 2008; 134: 329-340.
76. Foulquier F, Amyere M, Jaeken J, Zeevaert R, Schollen E, Race V, Bammens R, Morelle W, Rosnoblet C, Legrand D, Demaegd D, Buist N, Cheillan D, et al. TMEM165 deficiency causes a congenital disorder of glycosylation. American Journal of Human Genetics. 2012; 91: 15-26.
77. Jetten AM. Retinoid-related orphan receptors (RORs): critical roles in development, immunity, circadian rhythm, and cellular metabolism. Nuclear receptor signaling. 2009; 7: e003.
78. Guillaumond F, Dardente H, Giguere V, Cermakian N. Differential control of Bmal1 circadian transcription by REV-ERB and ROR nuclear receptors. Journal of Biological Rhythms. 2005; 20: 391-403.
79. Du J, Xu R. RORalpha, a potential tumor suppressor and therapeutic target of breast cancer. International journal of molecular sciences. 2012; 13: 15755-15766.
80. Ranhotra HS. The interplay between retinoic acid receptorrelated orphan receptors and human diseases. Journal of receptor and signal transduction research. 2012; 32: 181-189.
81. Feng S, Xu S, Wen Z, Zhu Y. Retinoic acid-related orphan receptor RORbeta, circadian rhythm abnormalities and tumorigenesis (Review). International journal of molecular medicine. 2015; 35: 1493-1500.
82. Xiong G, Wang C, Evers BM, Zhou BP, Xu R. RORalpha suppresses breast tumor invasion by inducing SEMA3F expression. Cancer research. 2012; 72: 1728-1739.
83. Zhu Y, McAvoy S, Kuhn R, Smith DI. RORA, a large common fragile site gene, is involved in cellular stress response. Oncogene. 2006; 25: 2901-2908.
84. Davidson B, Abeler VM, Forsund M, Holth A, Yang Y, Kobayashi Y, Chen L, Kristensen GB, Shih I, Wang TL. Gene expression signatures of primary and metastatic uterine leiomyosarcoma. Human pathology. 2014; 45: 691-700.
85. Risinger J, Allard J, Chandran U, Day R, Chandramouli G, Miller C, Zahn C, Oliver J, Litzi T, Marcus C. Gene expression analysis of early stage endometrial cancers reveals unique transcripts associated with grade and histology but not depth of invasion. Frontiers in oncology. 2013; 3: 139.
86. Cao Q, Gery S, Dashti A, Yin D, Zhou Y, Gu J, Koeffler HP. A role for the clock gene per1 in prostate cancer. Cancer research. 2009; 69: 7619-7625.
87. Chen ST, Choo KB, Hou MF, Yeh KT, Kuo SJ, Chang JG. Deregulated expression of the PER1, PER2 and PER3 genes in breast cancers. Carcinogenesis. 2005; 26: 1241-1246.
88. Fan W, Chen X, Li C, Yongluo, Chen L, Liu P, Chen Z. The analysis of deregulated expression and methylation of the PER2 genes in gliomas. Journal of cancer research and therapeutics. 2014; 10: 636-640.
89. Fonnes S, Donatsky AM, Gogenur I. Expression of core clock genes in colorectal tumour cells compared with normal mucosa: a systematic review of clinical trials. Colorectal disease. 2015; 17: 290-297.
90. Fu L, Pelicano H, Liu J, Huang P, Lee C. The circadian gene Period2 plays an important role in tumor suppression and DNA damage response in vivo. Cell. 2002; 111: 41-50.
91. Mostafaie N, Kallay E, Sauerzapf E, Bonner E, Kriwanek S, Cross HS, Huber KR, Krugluger W. Correlated downregulation of estrogen receptor beta and the circadian clock gene Per1 in human colorectal cancer. Molecular carcinogenesis. 2009; 48: 642-647.
92. Kelleher FC, Rao A, Maguire A. Circadian molecular clocks and cancer. Cancer letters. 2014; 342: 9-18.
93. Benna C, Scannapieco P, Piccin A, Sandrelli F, Zordan M, Rosato E, Kyriacou CP, Valle G, Costa R. A second timeless gene in Drosophila shares greater sequence similarity with mammalian tim. Current biology. 2000; 10: R512-3.
94. Gotter AL, Manganaro T, Weaver DR, Kolakowski LF,Jr, Possidente B, Sriram S, MacLaughlin DT, Reppert SM. A time-less function for mouse timeless. Nature neuroscience. 2000; 3: 755-756.
95. Engelen E, Janssens RC, Yagita K, Smits VA, van der Horst GT, Tamanini F. Mammalian TIMELESS is involved in period determination and DNA damage-dependent phase advancing of the circadian clock. PloS one. 2013; 8: e56623.
96. Mazzoccoli G, Laukkanen MO, Vinciguerra M, Colangelo T, Colantuoni V. A Timeless Link Between Circadian Patterns and Disease. Trends in molecular medicine. 2016; 22: 68-81.
97. Rana S, Mahmood S. Circadian rhythm and its role in malignancy. Journal of circadian rhythms. 2010; 8: 3-3391-8-3.
98. Nakahata Y, Sahar S, Astarita G, Kaluzova M, Sassone-Corsi P. Circadian control of the NAD+ salvage pathway by CLOCK-SIRT1. Science (New York, N.Y.). 2009; 324: 654-657.
99. Panda S. Circadian physiology of metabolism. Science. 2016; 354: 1008-1015.
100. Bass J, Lazar MA. Circadian time signatures of fitness and disease. Science. 2016; 354: 994-999.
101. He C, Anand ST, Ebell MH, Vena JE, Robb SW. Circadian disrupting exposures and breast cancer risk: a meta-analysis. International archives of occupational and environmental health. 2015; 88: 533-547.
102. Schernhammer ES, Laden F, Speizer FE, Willett WC, Hunter DJ, Kawachi I, Fuchs CS, Colditz GA. Night-shift work and risk of colorectal cancer in the nurses' health study. Journal of the National Cancer Institute. 2003; 95: 825-828.
103. Parent ME, El-Zein M, Rousseau MC, Pintos J, Siemiatycki J. Night work and the risk of cancer among men. American Journal of Epidemiology. 2012; 176: 751-759.
104. Lane JM, Vlasac I, Anderson SG, Kyle SD, Dixon WG, Bechtold DA, Gill S, Little MA, Luik A, Loudon A, Emsley R, Scheer FA, Lawlor DA, et al. Genome-wide association analysis identifies novel loci for chronotype in 100,420 individuals from the UK Biobank. Nature communications. 2016; 7: 10889.
105. Kalmbach DA, Schneider LD, Cheung J, Bertrand SJ, Kariharan T, Pack AI, Gehrman PR. Genetic basis of chronotype in humans: Insights from three landmark GWAS. Sleep. 2016.
106. Dickerman BA, Markt SC, Koskenvuo M, Hublin C, Pukkala E, Mucci LA, Kaprio J. Sleep disruption, chronotype, shift work, and prostate cancer risk and mortality: a 30-year prospective cohort study of Finnish twins. Cancer Causes Control. 2016; 27: 1361-1370.
107. Erren TC, Morfeld P, Gross VJ. Night shift work, chronotype, and prostate cancer risk: Incentives for additional analyses and prevention. International journal of cancer. 2015; 137: 1784-1785.
108. Papantoniou K, Castano-Vinyals G, Espinosa A, Aragones N, Perez-Gomez B, Burgos J, Gomez-Acebo I, Llorca J, Peiro R, Jimenez-Moleon JJ, Arredondo F, Tardon A, Pollan M, et al. Night shift work, chronotype and prostate cancer risk in the MCC-Spain case-control study. International journal of cancer. 2015; 137: 1147-1157.
109. Papantoniou K, Castano-Vinyals G, Espinosa A, Aragones N, Perez-Gomez B, Ardanaz E, Altzibar JM, Sanchez VM, Gomez-Acebo I, Llorca J, Munoz D, Tardon A, Peiro R, et al. Breast cancer risk and night shift work in a casecontrol study in a Spanish population. European journal of epidemiology. 2016; 31: 867-878.
110. Urlep Z, Rozman D. The Interplay between Circadian System, Cholesterol Synthesis, and Steroidogenesis Affects Various Aspects of Female Reproduction. Frontiers in endocrinology. 2013; 4: 111.
111. Kourtidis A, Jain R, Carkner RD, Eifert C, Brosnan MJ, Conklin DS. An RNA interference screen identifies metabolic regulators NR1D1 and PBP as novel survival factors for breast cancer cells with the ERBB2 signature. Cancer research. 2010; 70: 1783-1792.
112. Lazar MA, Hodin RA, Darling DS, Chin WW. A novel member of the thyroid/steroid hormone receptor family is encoded by the opposite strand of the rat c-erbA alpha transcriptional unit. Molecular and cellular biology. 1989; 9: 1128-1136.
113. van de Vijver M, van de Bersselaar R, Devilee P, Cornelisse C, Peterse J, Nusse R. Amplification of the neu (c-erbB-2) oncogene in human mammmary tumors is relatively frequent and is often accompanied by amplification of the linked c-erbA oncogene. Molecular and cellular biology. 1987; 7: 2019-2023.
114. Hurtado A, Holmes KA, Geistlinger TR, Hutcheson IR, Nicholson RI, Brown M, Jiang J, Howat WJ, Ali S, Carroll JS. Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen. Nature. 2008; 456: 663-666.
115. Wang B, Dai ZM, Zhao Y, Wang XJ, Kang HF, Ma XB, Lin S, Wang M, Yang PT, Dai ZJ. Current evidence on the relationship between two common polymorphisms in NPAS2 gene and cancer risk. International journal of clinical and experimental medicine. 2015; 8: 7176-7183.
116. Geng P, Ou J, Li J, Wang N, Xie G, Sa R, Liu C, Xiang L, Liang H. Genetic association between PER3 genetic polymorphisms and cancer susceptibility: a meta-analysis. Medicine. 2015; 94: e568.
117. Mocellin S, Verdi D, Pooley KA, Nitti D. Genetic variation and gastric cancer risk: a field synopsis and meta-analysis. Gut. 2015; 64: 1209-1219.